AQL™-Naltrexone
Opioid Use Disorder
Pre-clinicalActive
Key Facts
About Plumb Pharmaceuticals
Plumb Pharmaceuticals is a private, preclinical-stage biotech founded in 2016 to commercialize its Advanced Quantload (AQL™) platform for ultra-long-acting drug delivery. Its lead program is an injectable, subcutaneous naltrexone formulation for opioid use disorder designed to last significantly longer than the current market leader, Vivitrol®, with a potentially improved tolerability profile. The company has secured seed financing and holds key patents for its liposome-based technology, positioning it to address major compliance challenges in chronic conditions like addiction and pain.
View full company profileTherapeutic Areas
Other Opioid Use Disorder Drugs
| Drug | Company | Phase |
|---|---|---|
| TRV734 | Trevena | Phase 1 |
| FP-004 (SIF Formulation) | Foresee Pharmaceuticals | Preclinical |
| Vaxine Opioid Addiction Vaccine | Vaxine | Preclinical |
| Safer Ibogaine Analogs | Gilgamesh Pharmaceuticals | Pre-clinical/Research |
| AM-510 | Aion Medicines | Discovery |
| Naltrexone Implant | Delpor | Phase 1 |
| Platform Expansion | Amygdala Neurosciences | Research |
| Undisclosed OUD Program | Epiodyne | Pre-clinical |
| MEB-1170 | Mebias Discovery | Phase 1 |
| SUBLOCADE® | Indivior PLC | Marketed |